Zentaris GmbH
Records under this name other than the patents Zentaris GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,710,089 | Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors Formerly held Lapsed on the fee record Ended Apr 29, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 29, 2026 | USPTO record |
| US 8,669,091 | Microorganisms as Carriers of Nucleotide Sequences Coding for Antigens and Protein Toxins, Process of Manufacturing and Uses Thereof Formerly held Lapsed on the fee record Ended Mar 11, 2026 · High confidence | Lapsed on the fee record | Ended Mar 11, 2026 | High confidence |
| US 7,887,817 | Process for preventing protozoal diseases Formerly held Term ended Term ended Dec 22, 2024 · USPTO record | Term ended | Term ended Dec 22, 2024 | USPTO record |
| US 8,551,977 | Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals Formerly held Term ended Term ended Jan 31, 2024 · USPTO record | Term ended | Term ended Jan 31, 2024 | USPTO record |
| US 7,884,071 | Administration form for pharmaceutically active peptides with sustained release and method for the production thereof Term ended Term ended Nov 27, 2023 · USPTO record | Term ended | Term ended Nov 27, 2023 | USPTO record |
| US 7,214,662 | Injectable solution of an LHRH antagonist Formerly held Term ended Term ended Oct 29, 2023 · USPTO record | Term ended | Term ended Oct 29, 2023 | USPTO record |
| US 7,790,686 | Injection solution of an LHRH antagonist Formerly held Term ended Term ended Oct 28, 2023 · USPTO record | Term ended | Term ended Oct 28, 2023 | USPTO record |
| US 8,389,497 | Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals Term ended Ended no later than Jul 30, 2023 · USPTO record | Term ended | Ended no later than Jul 30, 2023 | USPTO record |
| US 7,098,305 | Sustained release of microcrystalline peptide suspensions Formerly held Term ended Term ended Apr 9, 2023 · USPTO record | Term ended | Term ended Apr 9, 2023 | USPTO record |
| US 6,816,032 | Laminated Low-Profile Dual Filter Module for Telecommunications Devices and Method Therefor Formerly held Term ended Term ended Sep 3, 2022 · High confidence | Term ended | Term ended Sep 3, 2022 | High confidence |